COMP <GO>
GDTC vs LTRN // EV/EBITDA & P/E VALUATION
CytoMed Therapeutics Limited (NASDAQ) VS. Lantern Pharma Inc. (NASDAQ) • 15-METRIC TALLY: GDTC 1
— LTRN 1
■ METRIC PARITY
LAST: $0.90 (-3.68%) • MKT CAP: $10.7M
valuation
—
LAST: $0.73 (-5.52%) • MKT CAP: $10.9M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GDTC VS. LTRN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GDTC | LTRN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 3/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.9 | 31.5 | +20.46 | GDTC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.7M | $10.9M | -$265.2K | LTRN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GDTC REV | LTRN REV | GDTC GROSS % | LTRN GROSS % | GDTC FCF | LTRN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $0 | — | — | — | -$15.7M |
| FY 2024 | — | $0 | — | — | — | -$17.8M |
| FY 2023 | — | $0 | — | — | — | -$14.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GDTC // BETA —
LTRN // BETA —